- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Drugs ceiling prices to be revised every 5 years: DoP amends DPCO 2013 Act
New Delhi: Through a recent gazette notification, Department of Pharmaceuticals (DoP), under the Ministry of Chemicals and Fertilizers, has decided that the ceiling price for formulations specified under SCHEDULE – I will be fixed every five years from the date of fixing the ceiling price.
This order has been brought to effect with a recent amendment in paragraph 18 of the Drugs Prices Control Order (DPCO), 2013.
With the amendment, the Department of Pharmaceuticals has excluded a provision in the Drugs (Prices Control) Order, 2013, that allowed a price revision on drugs based on Moving Annual Turnover (MAT) when the Ministry of Health and Family Welfare revises the National List of Essential Medicines (NLEM).
This came in line with the amendment made by the Department of Pharmaceuticals in the Drugs (Prices Control) Order, 2013, in paragraph 18, for clause (i).
As per the Drugs (Prices Control) Order, 2013, paragraph 18, clause (i), "The revision of ceiling prices on the basis of moving annual turnover value shall be carried out,-(i) as and when the National List of Essential Medicines is revised by the Ministry of Health and Family Welfare or five years from the date of fixing the ceiling price under this Order, whichever is earlier;"
According to the new amendment, the clause now simply specifies that the price revision can be conducted every five years from the date of setting the cap price.
The gazette notification said,
"In exercise of the powers conferred by section 3 of the Essential Commodities Act, 1955 (10 of 1955), the Central Government hereby makes the following Order further to amend the Drugs (Prices Control) Order, 2013, namely:-
1. Short title and commencement.-
(1) This Order may be called the Drugs (Prices Control) Third Amendment Order, 2021.
(2) It shall come into force on the date of its publication in the Official Gazette.
2. In the Drugs (Prices Control) Order, 2013, in paragraph 18, for clause (i), the following clause shall be substituted, namely:-
"(i) every five years from the date of fixing the ceiling price under this Order for formulations as specified under the SCHEDULE - I."
To view Gazette, click on the link below-
Also Read: NPPA directs pharma firms to provide PTR, MAT details for 29 formulations